Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting

Cancers

Luciana Trane¹  Caterina Longo²  Emi Dika³  Francesco De Rosa⁴  Giuseppe Spinelli⁵  Silvia Scoccianti⁶  Federico Venturi⁷  Biancamaria Zuccaro⁷  Vincenzo De Giorgi⁷  Flavia Silvestri⁷  Federica Scarfì⁷ 

[1] Cancer Research “AttiliaPofferi” Foundation, 50100 Pistoia, Italy;Department of Dermatology, University of Modena and Reggio Emilia, 42100 Modena, Italy;Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy;Immunotherapy-Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) “Dino Amadori” IRCCS, 47014 Meldola, Italy;Maxillofacial Surgery Department, Azienda Ospedaliero-Universitaria Careggi, 50100 Florence, Italy;Radiation Oncology Unit, Azienda Toscana Centro, 50100 Florence, Italy;Section of Dermatology, Department of Health Sciences, University of Florence, 50100 Florence, Italy;

关键词: skin cancer;    vismodegib;    sonidegib;    therapy;    cemiplimab;   

DOI  :  10.3390/cancers13225706

来源: DOAJ

【 摘 要 】

Despite recent progress and the publishing of several clinical guidelines on the management of advanced basal cell carcinoma, there is still no comprehensive set of clinical guidelines addressing the complexity inherent to the use of Hedgehog pathway inhibitors in the treatment of advanced basal cell carcinoma in real-world clinical practice. To develop practical and valuable tools that help specialists improve the clinical management of these patients, we sought the opinion of expert physicians with extensive knowledge and experience in the treatment of advanced basal cell carcinoma.

【 授权许可】

Unknown